TABLE 1.

Amyloid Imaging AUC Guidelines

Clinical scenarioScore
Appropriate use (scores of 7–9)
 5. Patients with MCI or dementia who are <65 y old and in whom AD pathology is suspected9
 6. Patients with MCI or dementia syndrome that is often consistent with AD pathology (amnestic presentation), with onset at ≥65 y8
 7. Patients with MCI or dementia syndrome that could be consistent with AD pathology but has atypical features (e.g., nonamnestic clinical presentation, rapid or slow progression, etiologically mixed presentation)8
 11. Patients with MCI or dementia with equivocal or inconclusive results on recent cerebrospinal fluid biomarkers8
 12. Patients with mild cognitive impairment due to clinically suspected AD pathology for whom information is needed to determine prognosis8
 14. Patients whose eligibility for treatment with approved amyloid-targeting therapy must be determined9
 15. Patients whose response must be monitored after receiving approved amyloid-targeting therapy8
Uncertain use (scores of 4–6)
 4. Patients with subjective cognitive decline (cognitively unimpaired based on objective testing) who are considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history6
 13. Patients with dementia due to clinically suspected AD pathology for whom information is needed to determine prognosis4
Rarely appropriate use (scores of 1–3)
 1. Patients cognitively unimpaired and not considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history1
 2. Patients cognitively unimpaired but considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history2
 3. Patients with subjective cognitive decline (cognitively unimpaired based on objective testing) who are not considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history2
 8. Patients with established biomarker-supported diagnosis of MCI or dementia due to AD pathology, for whom disease severity must be determined or disease progression tracked1
 9. Patients with prodromal Lewy body disease or dementia with Lewy bodies1
 10. Patients with MCI or dementia and recent cerebrospinal fluid biomarker results that are conclusive (whether consistent or not with underlying AD pathology)3
 16. For nonmedical use (e.g., legal, insurance coverage, or employment screening)1
 17. For use in lieu of genotyping, in patients who are suspected autosomal dominant mutation carriers1
  • Scenarios are numbered as in reference article (5). AUC are from (5).